Swiss Infrastructure Stock News

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...

Sulzer (SWX:SUN) has drawn investor attention after reporting record 2025 EBITDA of CHF 556 million, record sales and order intake, and proposing a higher annual dividend of CHF 4.75 per share. See our latest analysis for Sulzer. Despite the strong 2025 results and higher dividend proposal, Sulzer’s recent share price has cooled, with a 1-day share price return decline of 1.53% and a 7-day share price return decline of 4.56%, while the 90-day share price return of 19.57% and 3-year total...

Siegfried Holding AG has reported past full-year 2025 results, with sales rising to CHF 1,327.83 million and net income to CHF 168.66 million, alongside higher basic and diluted earnings per share from continuing operations. At the same time, Siegfried is reshaping its operations by consolidating its Chief Operating Officer roles, as the COO for Drug Substances departs and an interim leader assumes expanded responsibilities. We’ll now examine how Siegfried’s higher full-year earnings and COO...

Why the infant formula recalls matter for Nestlé (SWX:NESN) Nestlé (SWX:NESN) is under close watch after recalling infant formula products in more than 60 countries due to low levels of the cereulide toxin, prompting tighter safety controls and raising fresh questions for shareholders about risk and resilience. See our latest analysis for Nestlé. Despite concerns around the recalls, Nestlé’s recent 30 day share price return of 13.32% and year to date share price return of 8.86% contrast with...

The latest earnings release from u-blox Holding (SWX:UBXN) put a sharp 54.43% FY 2024 revenue decline in focus, prompting investors to reassess margin pressure, liquidity strength, and R&D-heavy exposure to AI-enabled positioning markets. See our latest analysis for u-blox Holding. At a share price of CHF135.0, u-blox has seen strong momentum recently, with an 81.21% year to date share price return and a 108.01% total shareholder return over the past year. This suggests sentiment has shifted...

If you are wondering whether Roche Holding's current share price offers good value, you are not alone. This article will focus squarely on what investors may be paying for today. Roche's shares most recently closed at CHF 362.90, with a 2.0% decline over the last 7 days, a 3.5% gain over 30 days, 11.5% year to date, 23.9% over 1 year, 49.6% over 3 years and 41.3% over 5 years. Recent market attention on Roche has been driven by ongoing developments in its pharmaceuticals and diagnostics...

Recent commentary around rapid growth in digital mining, particularly for lithium and copper related to electric vehicles and the energy transition, has put ABB (SWX:ABBN) in focus as it expands partnerships and mining technologies. See our latest analysis for ABB. Against this backdrop of digital mining partnerships and technology deployments, ABB’s share price sits at CHF70.64, with a 90 day share price return of 22.98% and a 1 year total shareholder return of 47.76%. This suggests momentum...

Upcoming earnings put Comet Holding (SWX:COTN) under the AI spotlight Investor attention is building ahead of Comet Holding (SWX:COTN)'s 6 March 2026 earnings update, as the market looks for fresh clarity on AI linked semiconductor demand and order momentum in its Plasma Control Technologies division. See our latest analysis for Comet Holding. At a share price of CHF292.4, Comet is trading close to its 52 week high after a 90 day share price return of 38.71%, while the 1 year total...

Intershop Holding AG reported full-year 2025 results, with sales of CHF 86.54 million, revenue of CHF 119.11 million and net income of CHF 212.79 million, and announced an annual dividend of CHF 6.00 per share payable on April 8, 2026. The sharp increase in earnings per share from continuing operations to CHF 23.09 highlights how earnings growth is supporting Intershop Holding’s capacity to return cash to shareholders via a higher dividend. We’ll now examine how Intershop Holding’s strong...

Why Novartis is on investors’ radar today Novartis (SWX:NOVN) is in focus for investors after a strong run recently, with the share price showing double digit returns over the past month and the past 3 months. This performance is prompting closer attention to valuations. See our latest analysis for Novartis. Looking beyond the recent surge, Novartis’ share price is now at CHF130.5, with a 30 day share price return of 13.85% and a year to date share price return of 20.28%. The 1 year total...

Earnings trigger and why ARYZTA is back on investors’ radar ARYZTA (SWX:ARYN) has just reported its 2025 results, with revenue at €2.223b, a 1.5% increase, supported by free cash flow and cost saving efforts that include efficiency programs across the business. The company also announced plans to introduce a capital return policy in 2026 and highlighted an expectedly stronger balance sheet, developments that help explain why the stock is attracting fresh attention today. See our latest...

ams-OSRAM (SWX:AMS) is in the middle of a wide ranging shake-up, selling non optical sensor and specialty lamp businesses, cutting 2,000 jobs and pursuing sizeable cost savings to reshape its photonics and automotive focus. See our latest analysis for ams-OSRAM. These portfolio moves come after a period where the 90 day share price return of 20.46% contrasts with a 1 year total shareholder return of a 10.30% decline. This suggests some short term momentum while long term holders remain under...

dormakaba Holding (SWX:DOKA) moved into focus after its H1 2026 results, reporting sales of CHF 1,362.7 million and net income of CHF 40.5 million, both below the prior half year. See our latest analysis for dormakaba Holding. The H1 2026 earnings release helps explain why the 90 day share price return sits at a decline of 13.01%, even though the 3 year total shareholder return is a gain of 41.09% and recent momentum has weakened despite a 3.60% 1 day share price return to CHF57.5. If this...

If you are wondering whether UBS Group shares are offering fair value right now, you are not alone. The stock has attracted plenty of attention from investors weighing up risk and reward. The share price closed at CHF32.01, with a 6.9% return over the last year, set against a 16.1% decline year to date, a 12.5% decline over 30 days and a 2.4% decline over the past week as investors reassess their stance. Recent headlines around UBS Group have focused on its ongoing integration work and...

Zug Estates Holding AG reported past full-year 2025 results on February 19, 2026, with sales of CHF 87.72 million, revenue of CHF 91.5 million and net income of CHF 85.18 million, and announced an annual dividend of CHF 49.00 per share payable on April 14, 2026. The combination of higher earnings and a substantial cash return through the increased dividend highlights how the company is converting operating performance into shareholder payouts. With stronger full-year profitability and a...

Intershop Holding (SWX:ISN) has released its full year 2025 figures, reporting CHF 119.11 million in revenue and CHF 212.79 million in net income, and confirming an annual dividend of CHF 6.00 per share. See our latest analysis for Intershop Holding. At a share price of CHF 170.60, Intershop Holding has seen a 6.62% 90 day share price return and a 28.46% 1 year total shareholder return. This suggests momentum has been building around the latest earnings and dividend updates. If strong results...

Why Allreal Holding’s latest earnings matter for shareholders Allreal Holding (SWX:ALLN) has just posted its 2025 full year results, reporting CHF 436.7 million in revenue and CHF 219.3 million in net income, with earnings per share from continuing operations at CHF 13.28. See our latest analysis for Allreal Holding. The latest full year earnings news appears to have landed in a market that was already warming to Allreal Holding, with a 30 day share price return of 4.42% and a 90 day share...

Sulzer AG has reported its full-year 2025 results, with sales of CHF 3,555.4 million, net income of CHF 292.8 million, and record EBITDA of CHF 556 million, marking a third consecutive year of margin expansion despite currency and geopolitical pressures. An increased dividend, a higher-margin aftermarket business now contributing 62% of turnover, and record profitability across divisions highlight how Sulzer’s operational excellence and services focus are reshaping its earnings...

Clariant (SWX:CLN) just posted its FY 2025 numbers with first half revenue of CHF 1,981 million and basic EPS of CHF 0.08, setting a cautious tone against a backdrop of trailing 12 month revenue of CHF 3,915 million and a basic EPS loss of CHF 0.23. The company has seen revenue hold in a tight band from CHF 2,070 million in the first half of 2024 to CHF 2,082 million in the second half of 2024, alongside EPS moving from CHF 0.48 to CHF 0.26. This now feeds into a mixed margin picture for...

European Commission grants marketing authorization for Ranluspec, a Sandoz biosimilar for major retinal diseases, with a planned European launch in the second half of 2026. US FDA approves an expanded label for Enzeevu, adding new retinal indications to Sandoz Group's ophthalmology offering. Both moves reinforce Sandoz Group's focus on biosimilars in eye care and broaden its addressable market in ophthalmology. Sandoz Group (SWX:SDZ) is leaning further into its biosimilar focus, with...

Dividend affirmation and new medium term plan draw fresh attention Graubündner Kantonalbank (SWX:GRKP) has affirmed an annual dividend of CHF 47.50 per share, with the payout set for 17 March 2026, following its 2025 results and the introduction of a new plan for 2026 to 2030. See our latest analysis for Graubündner Kantonalbank. At a share price of CHF 2,070.00, Graubündner Kantonalbank has posted a 14.36% 90 day share price return and an 18.45% 1 year total shareholder return, suggesting...

Adecco Group (SWX:ADEN) has proposed three new nominees for its Board of Directors: Tobias Knechtle, Matthias Rebellius, and Jacques Sanche. Two longstanding board members, Kathleen Taylor and Didier Lamouche, are planned to step down from their roles. The changes represent a significant shift in board composition for one of the world's largest staffing firms. Adecco Group, listed in Switzerland under SWX:ADEN, operates at the center of global staffing, recruitment, and workforce solutions...

Galderma Group (SWX:GALD) has put fresh clinical data for Nemluvio front and center, as new results from the long term OLYMPIA extension study in prurigo nodularis refocus investor attention on its therapeutic dermatology portfolio. See our latest analysis for Galderma Group. At a share price of CHF145.9, Galderma’s recent OLYMPIA data and Restylane device approval arrive after a 1 year total shareholder return of 32.93%, even as the year to date share price return sits at an 8.87% decline...